CA2761298A1 - Treatment of mci and alzheimer's disease - Google Patents

Treatment of mci and alzheimer's disease Download PDF

Info

Publication number
CA2761298A1
CA2761298A1 CA2761298A CA2761298A CA2761298A1 CA 2761298 A1 CA2761298 A1 CA 2761298A1 CA 2761298 A CA2761298 A CA 2761298A CA 2761298 A CA2761298 A CA 2761298A CA 2761298 A1 CA2761298 A1 CA 2761298A1
Authority
CA
Canada
Prior art keywords
nifedipine
nitroso
effective amount
therapeutically effective
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2761298A
Other languages
English (en)
French (fr)
Inventor
Mark Lovell
Bert Lynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kentucky Research Foundation
Original Assignee
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kentucky Research Foundation filed Critical University of Kentucky Research Foundation
Publication of CA2761298A1 publication Critical patent/CA2761298A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2761298A 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease Abandoned CA2761298A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21645209P 2009-05-15 2009-05-15
US61/216,452 2009-05-15
US23455109P 2009-08-17 2009-08-17
US61/234,551 2009-08-17
PCT/US2010/034721 WO2010132671A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2761298A1 true CA2761298A1 (en) 2010-11-18

Family

ID=43069025

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2761298A Abandoned CA2761298A1 (en) 2009-05-15 2010-05-13 Treatment of mci and alzheimer's disease

Country Status (7)

Country Link
US (1) US20100292281A1 (enExample)
EP (1) EP2429992A4 (enExample)
JP (1) JP2012526844A (enExample)
AU (1) AU2010249015A1 (enExample)
CA (1) CA2761298A1 (enExample)
MX (1) MX2011012015A (enExample)
WO (1) WO2010132671A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2578226B1 (en) 2004-08-23 2017-10-25 Yeda Research And Development Co., Ltd. Peptide for treating amyotrophic lateral sclerosis
AU2006299645B2 (en) 2005-09-30 2011-02-03 Io Therapeutics, Llc Treatment of cancer with specific RXR agonists
US20140088017A1 (en) 2011-05-23 2014-03-27 Yeda Research And Development Co., Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
CA2838562A1 (en) * 2011-08-08 2013-02-14 Eugenia Wang Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US20130190395A1 (en) 2011-12-13 2013-07-25 Dartmouth College Autoimmune disorder treatment using rxr agonists
BR112014031154A2 (pt) 2012-06-15 2017-08-08 Foundation For Biomedical Res And Innovation agente profilático e/ou terapêutico para deficiência cognitiva leve; e agente de melhoria do fluxo intersticial
US8901305B2 (en) * 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US20150045353A1 (en) * 2013-08-09 2015-02-12 Neurogenetic Pharmaceuticals, Inc. Formulations containing gamma secretase modulators, methods for preparation and delivery thereof
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
CA3016876C (en) 2016-03-10 2021-12-28 Io Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US10835507B2 (en) 2016-03-10 2020-11-17 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
CA3076373A1 (en) * 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2126533A1 (de) * 1971-05-28 1972-12-14 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur Herstellung pharma zeutischer Zubereitungen
DE4342196A1 (de) * 1993-12-10 1995-06-14 Bayer Ag Neue 4-Phenyl-substituierte 1,4-Dihydropyridine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ATE548351T1 (de) * 1996-01-29 2012-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Dihydropyridin-pyridin-, benzopyranon- und triazolochinazolin-derivate, deren herstellung und verwendung als adenosinrezeptor-antagonisten
AU2794199A (en) * 1998-02-26 1999-09-15 Robertas Bunevicius Thyroid hormone replacement using sustained release triiodothyronine
US6558650B1 (en) * 1998-04-08 2003-05-06 Oregon Health And Science University Enhancement of cellular gallium uptake
CN100444840C (zh) * 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
JP2007512339A (ja) * 2003-11-21 2007-05-17 メモリー・ファーマシューティカルズ・コーポレイション 記憶障害の処置における（＋）−イソプロピル２−メトキシエチル４−（２−クロロ−３−シアノ−フェニル）−１，４−ジヒドロ−２，６−ジメチル−ピリジン−３，５−ジカルボキシラートの使用
BRPI0518151A2 (pt) * 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
ATE526965T1 (de) * 2005-04-15 2011-10-15 Res & Innovation S P A Verfahren zur prävention, verzögerung oder umkehr von abnormer amyloid-ablagerung
JP2008539255A (ja) * 2005-04-26 2008-11-13 マイクロビア インコーポレーテッド 高コレステロール血症のための４−ビアリーリル−１−フェニルアゼチジン−２−オングルクロニド誘導体
JP2007091664A (ja) * 2005-09-29 2007-04-12 Univ Of Tokushima 細胞膜保護剤
JP5043677B2 (ja) * 2005-12-02 2012-10-10 持田製薬株式会社 アルツハイマー型認知症予防・治療剤
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
WO2008051291A2 (en) * 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
JP2009073759A (ja) * 2007-09-20 2009-04-09 Univ Of Tokushima Ｉｃａｍ−１発現抑制剤

Also Published As

Publication number Publication date
US20100292281A1 (en) 2010-11-18
WO2010132671A1 (en) 2010-11-18
EP2429992A1 (en) 2012-03-21
EP2429992A4 (en) 2012-11-28
AU2010249015A1 (en) 2011-11-24
MX2011012015A (es) 2012-04-30
JP2012526844A (ja) 2012-11-01

Similar Documents

Publication Publication Date Title
US20100292281A1 (en) Treatment of mci and alzheimer's disease
JP2012526844A5 (enExample)
AU2010353287A1 (en) Treatment of MCI and Alzheimer's disease
Das et al. A close look at BACE1 inhibitors for Alzheimer’s disease treatment
Pohanka Alzheimer s disease and oxidative stress: a review
Fernandez‐Perez et al. Synaptic dysregulation and hyperexcitability induced by intracellular amyloid beta oligomers
EP3560496A1 (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US9968574B2 (en) Treatment of MCI and Alzheimer's disease
KR20100137576A (ko) 알츠하이머병을 포함하는 타우-관련 질병의 치료에서의 에포틸론 ｄ의 용도
WO2008006070A2 (en) Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
US20220054454A1 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
Sui et al. Scorpion venom heat-resistant synthesized peptide ameliorates epileptic seizures and imparts neuroprotection in rats mediated by NMDA receptors
US20100247688A1 (en) Pirenzepine and derivatives thereof as anti-amyloid agents
KR20110066623A (ko) Ｅｐｐｓ를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
Lovell et al. Treatment of MCI and Alzheimer's Disease
DK2462131T3 (en) Preparations and Methods for Treating Beta-Amyloid-Related Diseases
ES2449594T3 (es) Método para reducir deposición amiloide, neurotoxicidad amiloide y microgliosis con enantiomero (-)-nilvadipina
EP1874311B1 (en) A method for preventing, delaying or reverting abnormal amyloid deposition
Samentar et al. A novel hybrid protein promotes Aβ clearance and reduces inflammatory response through MerTK
Hammond et al. P2–003: Effects of antibiotic treatment on cellular inflammatory processes in the brain during persistent Chlamydia pneumoniae infection of BALB/c mice
Mutoh Drug discovery in Alzheimer’s disease using metal chelators: Warning toward their usage
Giubilei Beyond Cholinesterase inhibition: anti-inflammatory role and pharmacological profile of current drug therapy for Alzheimer’s disease
Ranade et al. TARGET EVOLUTION AND THERAPY ADVANCEMENTS FOR ALZHEIMER’S DISEASE: A REVIEW

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160513